Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
14 - Pharmacogenetics of Diabetes
from II - Therapeutic Areas
Published online by Cambridge University Press: 05 June 2012
Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
Summary
Health Impact
Diabetes mellitus has become a major public health epidemic, affecting more than 250 million individuals worldwide in 2008, increasing to 380 million in 2025. Each year 3.8 million deaths are attributable to diabetes. An even greater number die of cardiovascular disease made worse by diabetes-related lipid disorders and hypertension (1).
Type 2 diabetes is much more common than type 1 diabetes, and accounts for approximately 90 percent of all diabetes worldwide (2). Type 1 diabetes is characterized by a lack of production of insulin in the body, whereas type 2 diabetes is due to the body's diminished insulin secretion from pancreatic β-cells and the resistance of tissues to insulin (3).
- Type
- Chapter
- Information
- Principles of Pharmacogenetics and Pharmacogenomics , pp. 145 - 153Publisher: Cambridge University PressPrint publication year: 2012
References
2007 http://www.idf.org
2008 http://www.who.int/mediacentre/factsheets/fs312/en/index.html
Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategiesJ Am Pharm Assoc 2009 49 S3Google Scholar
Carbohydrate metabolism in non-insulin-dependent diabetes mellitusN Engl J Med 1992 327 707Google Scholar
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med 2002 346 393Google Scholar
Glycemic control and the risk of multiple microvascular diabetic complicationsFam Med 2005 37 125Google Scholar
10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med 2008 359 1577Google Scholar
Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processesDiabetes 1998 47 345Google Scholar
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet 2006 368 1696Google Scholar
Biological effects and metabolic rates of glucagonlike peptide-17–36 amide and glucagonlike peptide-17–37 in healthy subjects are indistinguishableDiabetes 1993 42 658Google Scholar
Pharmacogenetics of metformin response: a step in the path toward personalized medicineJ Clin Invest 2007 117 1226Google Scholar
The antihyperglycaemic effect of metformin: therapeutic and cellular mechanismsDrugs 1999 58 31Google Scholar
Therapeutic roles of peroxisome proliferator-activated receptor agonistsDiabetes 2005 54 2460Google Scholar
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinideBr J Clin Pharmacol 2003 56 305Google Scholar
Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1–3)J Pharmacol Exp Ther 2004 308 2Google Scholar
Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogeneticsAnnu Rev Pharmacol Toxicol 2005 45 477Google Scholar
ATP-sensitive potassium channelopathies: focus on insulin secretionJ Clin Invest 2005 115 2047Google Scholar
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose rangeBr J Clin Pharmacol 2008 66 818Google Scholar
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteersClin Pharmacol Ther 2002 71 286Google Scholar
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agentsBr J Clin Pharmacol 2005 60 103Google Scholar
Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitusClin Pharmacol Ther 2008 83 288Google Scholar
Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteersClin Pharmacokinet 2004 43 267Google Scholar
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinideClin Pharmacol Ther 2003 74 380Google Scholar
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokineticsClin Pharmacol Ther 2005 77 468Google Scholar
Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideBr J Clin Pharmacol 2006 62 567Google Scholar
No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazoneBr J Clin Pharmacol 2008 65 78Google Scholar
Characterization of the cytochrome P450 enzymes involved in the metabolism of rosiglitazoneBr J Clin Pharmacol 1999 48 424Google Scholar
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitorsBasic Clin Pharmacol Toxicol 2006 99 44Google Scholar
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotypeClin Pharmacol Ther 2006 80 657Google Scholar
The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjectsBr J Clin Pharmacol 2006 62 682Google Scholar
The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjectsClin Pharmacol Ther 2005 59 70Google Scholar
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinideJ Clin Pharmacol 2008 48 311Google Scholar
Polymorphism in human organic cation transporters and metformin actionPharmacogenomics 2008 9 415Google Scholar
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metforminClin Pharmacol Ther 2009 86 299Google Scholar
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionJ Clin Invest 2007 117 1422Google Scholar
Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metforminJ Hum Genet 2007 52 117Google Scholar
Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitusPharmacogenomics J 2009 9 242Google Scholar
A human transporter protein that mediates the final excretion step for toxic organic cationsProc Natl Acad Sci USA 2005 102 17923Google Scholar
Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47ABiochem Pharmacol 2008 75 1689Google Scholar
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiportersBiochem Pharmacol 2007 74 359Google Scholar
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary studyDiabetes 2009 58 745Google Scholar
Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetesN Engl J Med 2004 1838Google Scholar
Common polymorphisms in the PPARgamma2 and IRS-1 genes and their interaction influence serum adiponectin concentration in young Finnish menMol Genet Metab 2005 84 344Google Scholar
The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetesDiabetes Care 2004 27 1394Google Scholar
The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndromeHum Reprod 2005 20 1207Google Scholar
Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention ProgramDiabetes 2007 56 531Google Scholar
Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analysesDiabet Med 2005 22 590Google Scholar
The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5ʹ-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetesJ Clin Endocrinol Metab 2006 91 2334Google Scholar
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetesNat Genet 2006 38 320Google Scholar
Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetesJ Clin Invest 2007 117 2155Google Scholar
Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs studyDiabetes 2007 56 2178Google Scholar
New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizersAnnu Rev Med 2001 52 239Google Scholar
The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetesNat Genet 2000 26 76Google Scholar
Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetesDiabetes Care 2003 26 825Google Scholar
Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) studyDiabetes Care 2004 27 1365Google Scholar
Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapyAnnu Rev Med 2008 59 95Google Scholar
Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetesClin Pharmacol Ther 2005 78 202Google Scholar
Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trialDiabetologia 2004 47 2176Google Scholar
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemiaJ Clin Endocrinol Metab 2001 86 1930Google Scholar
Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese populationDiabetes 2002 51 536Google Scholar
The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetesDiabetes Care 2005 28 1139Google Scholar
The common polymorphisms (single nucleotide polymorphism [SNP] +45 and SNP +276) of the adiponectin gene predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trialDiabetes 2005 54 893Google Scholar
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretinsRev Diabet Stud 2005 2 61Google Scholar
TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin actionDiabetes 2010 59 479Google Scholar